Metaxalone submicron

Drug Profile

Metaxalone submicron

Alternative Names: IC-1201; ICE-1201; Submicron metaxalone

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Muscle relaxants; Oxazolidinones; Small molecules
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Musculoskeletal disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-disorders in USA (PO, Tablet)
  • 12 Sep 2013 Top-line pharmacokinetics & adverse events data from a phase I trial in Healthy volunteers released by iCeutica
  • 31 Mar 2013 iCeutica completes phase I trials in Musculoskeletal disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top